Research programme: plasma kallikrein inhibitors - ActiveSite Pharmaceuticals

Drug Profile

Research programme: plasma kallikrein inhibitors - ActiveSite Pharmaceuticals

Alternative Names: ASP 400

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ActiveSite Pharmaceuticals
  • Developer ActiveSite Pharmaceuticals; AntriaBio
  • Class Small molecules
  • Mechanism of Action Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema; Hereditary angioedema
  • Discontinued Stroke

Most Recent Events

  • 09 Aug 2017 Discontinued - Preclinical for Stroke in USA (PO)
  • 07 Aug 2017 AntriaBio licenses ActiveSite Pharmaceuticals’ oral plasma kallikrein inhibitors for Diabetic macular oedema and Hereditary angioedema
  • 07 Aug 2017 Preclinical trials in Diabetic macular oedema in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top